# Eminent Venture Capital

> Eminent Venture Capital is a VC fund backing Biotechnology, Medical and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Feb 2023
- Lead investor: 0%
- Last updated: Aug 2026

Eminent Venture Capital is a private equity fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 100% |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Biopharma | 1 | 25% |
| Therapeutics | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 25% |
| Series D | 1 | 25% |
| Series E | 1 | 25% |
| Venture - Series Unknown | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NeOnc Technologies | NEONC Technologies, Inc. (NTI) is an early-stage cancer biotechnology company focused initially on intranasal (delivery through the nose) inhalation and other nontraditional delivery of a novel, highly purified form of monoterpenes (oils from fruits & plants), alone or with other chemotherapeutics (cancer treatment chemicals) agents. It willinitially be used in clinical research for first-line treatment of malignant brain cancer (gliomas) and other aggressive brain cancers, and later for the treatment of lung cancer.NTI was incorporated in the State of Delaware in 2008. The Company has assembled a highly qualified management team and board of directors. NTI is developing several proprietary molecules for clinical research some of which have demonstrated significant activity (positive results) in laboratory tests; NTI is accordingly building a portfolio of intellectual property around this research. In addition, the Company has reached an agreement with a manufacturer of active pharmaceutical ingredients for the development and production of proprietary monoterpenes. | $10M | Venture - Series Unknown | Feb 08, 2023 |  |
| Selecta Biosciences | Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $38M | Series E | Sep 08, 2015 |  |
| GlobeImmune | GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediatedcancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado. | $41.2M | Series C | Sep 26, 2007 |  |
| Nereus Pharmaceuticals | Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent forthe treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California. | $45M | Series D | Aug 09, 2007 |  |

4 of 4 investments shown.

## Co-investors
- Boston Life Science Venture — VC Fund, 2 deals together
- [Advent International](https://shizune.co/investors/profile/advent-international) — VC Fund, 1 deal together
- [Aju IB Investment](https://shizune.co/investors/profile/aju-ib-investment) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 1 deal together
- [BankInvest Biomedical Venture](https://shizune.co/investors/profile/bankinvest-biomedical-venture) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Eminent Venture Capital invest in?

Eminent Venture Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series D stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eminent Venture Capital last invest?

The most recent investment recorded for Eminent Venture Capital closed in Feb 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co